EU regulator backs Eisai-Biogen Alzheimer’s drug after initial rejection
The European Union’s drugs regulator on Thursday recommended approval of Eisai and Biogen’s Leqembi for some patients with early Alzheimer’s disease, reversing its initial decision from four months ago.